A Phase 2 interventional study of VX-670 in Myotonic Dystrophy Type 1 (DM1), sponsored by Vertex Pharmaceuticals Incorporated. Enrolling by invitation at 16 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Myotonic Dystrophy with a site in Canada — 13 open to participants now, 16 under way, 4 of them phase 3. Myotonic Dystrophy · Canada.
Among the 28 studies in Myotonic Dystrophy with a site in Canada, this one is the 11th largest by planned enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 11 of the 15 other live ones, and was the 24th registered.
126 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.
Browse Myotonic Dystrophy studies →13 of the 28 studies in Myotonic Dystrophy with a site in Canada are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in Canada, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
PepGen Inc · Sites in Canada
Sanofi · Sites in Canada, United States, Argentina and 3 more countries
Ages 10–55
PepGen Inc · Sites in Canada, New Zealand, Korea, Republic of and 1 more country
Ages 16–65
ARTHEx Biotech S.L. · Sites in Canada, United States, France and 4 more countries
Ages 18–64
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 11 · Phase 3 7
First in 2008; this study’s year is marked. 5 started in 2025.
This study's planned enrollment of 44 is close to the median of 40 across 67 interventional studies indexed under Myotonic Dystrophy.
Median enrollment 32 across the 25 interventional studies, 100 across the 3 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 28 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 55 (51%) have results posted.
Vertex Pharmaceuticals Incorporated has 2 studies filed under Myotonic Dystrophy — fewer than ten, so there is no comparison to draw.
7 of the studies in Myotonic Dystrophy with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05004129Phase 3AMO Pharma LimitedSafety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy | 2026-12-31 |
| NCT03981575Virginia Commonwealth UniversityEstab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | 2026-12-01 |
| NCT06316778Université de SherbrookePelvic Floor Muscle Training for Women with Myotonic Dystrophy | 2026-12-30 |
| NCT06138743Sarepta Therapeutics, Inc.Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy | 2026-12-31 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
Add all 7 to your calendar (.ics) → With an account.
Among the 28 studies in Myotonic Dystrophy with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Participants will receive multiple doses of VX-670.
Drug: VX-670
Solution for intravenous administration.
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Day 1 up to Week 108
Maximum Observed Concentration (Cmax) of VX-670 and its Active Component in Plasma
Time frame: From Day 1 up to Week 96
Area Under the Concentration Versus Time Curve (AUC) of VX-670 and its Active Component in Plasma
Time frame: From Day 1 up to Week 96
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Jan 2029, 45 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vertex Pharmaceuticals Incorporated →